Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT01507168 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Start date: February 2, 2012
Phase: Phase 2
Study type: Interventional

This randomized, placebo-controlled, multicenter study will evaluate the efficacy and safety of GC33 (RO5137382) in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma. Participants will be stratified according to the level of GPC-3 expression in tumors and randomized to receive either GC33 (1600 mg intravenously) or placebo on Days 1 and 8 of Cycle 1 and every 2 weeks thereafter. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

NCT ID: NCT01507064 Completed - Clinical trials for Hepatocellular Carcinoma

Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma

LANEX
Start date: January 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether neoadiuvant therapy with sorafenib increases the efficacy of thermal ablation in inducing the necrosis of hepatocellular carcinoma.

NCT ID: NCT01506115 Completed - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma

Start date: September 2009
Phase: N/A
Study type: Interventional

The prognosis of patients with obstructive jaundice caused by hepatocellular carcinoma (HCC) is dismal even after biliary drainage; due to malfunction of the biliary drainage tube caused by hemobilia and/or tumor emboli. Photodynamic therapy (PDT) in hilar cholangiocarcinoma improves biliary drainage and prolongs survival. The aims of this study were to assess the safety and efficacy of PDT in unresectable HCC with bile duct invasion.

NCT ID: NCT01505868 Completed - Clinical trials for Prostate Adenocarcinoma

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Start date: July 11, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This partially randomized phase I/II trial studies cabazitaxel with or without carboplatin in treating patients with previously treated prostate cancer that has spread to other areas of the body and does not respond to treatment with hormones. Drugs used in chemotherapy, such as cabazitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cabazitaxel alone or with carboplatin is more effective in treating prostate cancer.

NCT ID: NCT01504932 Completed - Tongue Cancer Clinical Trials

Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors

Start date: February 23, 2007
Phase: N/A
Study type: Interventional

This pilot clinical trial studies freeze-dried black raspberries (BRB) in preventing oral cancer recurrence in high at-risk Appalachian patients previously treated with surgery for oral cancer. Chemoprevention is the use of drugs natural products to keep cancer from developing, progressing, or recurring. Giving freeze-dried black raspberries may prevent oral cancer from forming or returning in oral cancer survivors.

NCT ID: NCT01504256 Completed - Clinical trials for Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

CatuNeo
Start date: October 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of catumaxomab by determination of the rate of macroscopic complete remissions of peritoneal carcinomatosis after treatment with one cycle (four doses) of catumaxomab followed by six cycles of routine neoadjuvant chemotherapy.

NCT ID: NCT01504126 Completed - Clinical trials for Ovarian Endometrioid Adenocarcinoma

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Start date: March 9, 2012
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies giving propranolol hydrochloride with standard chemotherapy in treating patients with ovarian, primary peritoneal, or fallopian tube cancer. Biological therapies, such as propranolol hydrochloride, blocks certain chemicals that affect the heart and this may stimulate the immune system and allow the chemotherapy to kill more tumor cells.

NCT ID: NCT01503229 Completed - Clinical trials for Metastatic Prostate Carcinoma

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Start date: December 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well abiraterone acetate works in treating patients with hormone-resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic). Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01502410 Completed - Clinical trials for Papillary Thyroid Cancer

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Start date: January 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01500954 Completed - Clinical trials for Cutaneous Squamous Cell Carcinoma

Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma

Start date: October 2011
Phase: N/A
Study type: Observational

MicroRNAs (miRNAs) are a novel class of short RNAs which have shown to be dysregulated in a variety of cancers. Data of miRNA expression in cutaneous squamous cell carcinoma (cSCC) is very limited and microarray based genome wide miRNA expression profiles of cSCC have not been investigated so far.